Antisense oligonucleotides: targeting oncogenic long non-coding RNAs for cancer therapy
- 14 March 2026
- journal article
- review article
- Published by Springer Nature in Biotechnology Letters
- Vol. 48 (2)
Abstract
This narrative review aims to summarize current evidence on antisense oligonucleotide (ASO)-based strategies targeting oncogenic long non-coding RNAs (lncRNAs) and to evaluate their therapeutic potential in cancer initiation, progression, metastasis, and treatment resistance. A narrative review of preclinical studies was conducted, focusing on ASO-mediated silencing of cancer-associated lncRNAs, including MALAT1, PVT1, NEAT1, and other emerging lncRNAs, across multiple malignancies such as lung, breast, ovarian, gastrointestinal, and head-and-neck cancers. Advances in ASO chemical design and delivery strategies-including lipid and polymeric nanoparticles, ligand-directed conjugates, peptide-based carriers, and gymnotic uptake-were also examined. Preclinical evidence consistently demonstrates that lncRNA-targeted ASOs effectively suppress tumor growth, invasion, metastasis, and chemoresistance while promoting apoptosis. Improvements in ASO chemical modifications and delivery platforms have significantly enhanced ASO stability, biodistribution, and intracellular uptake, thereby improving therapeutic efficacy across diverse cancer models. Targeting oncogenic lncRNAs using ASO-based approaches represents a promising and rapidly evolving strategy in precision oncology. Although substantial progress has been achieved in ASO design and delivery, further optimization and well-structured clinical trials are required to facilitate the translation of these therapies into routine cancer treatment.Keywords
Funding Information
- Arak University of Medical Sciences
This publication has 49 references indexed in Scilit:
- Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survivalOncogene, 2014
- PVT1 dependence in cancer with MYC copy-number increaseNature, 2014
- Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotidesExpert Opinion on Biological Therapy, 2013
- Long Noncoding RNAs: Cellular Address Codes in Development and DiseaseCell, 2013
- The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer CellsCancer Research, 2013
- Chemical Modification Study of Antisense GapmersNucleic Acid Therapeutics, 2012
- The hallmarks of cancerRNA Biology, 2012
- The Nuclear-Retained Noncoding RNA MALAT1 Regulates Alternative Splicing by Modulating SR Splicing Factor PhosphorylationMolecular Cell, 2010
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic PlatformAnnual Review of Pharmacology and Toxicology, 2010
- Antisense oligonucleotides: basic concepts and mechanisms.2002